Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.

Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in ...

Roche's Genentech unit has forged an alliance with Astex, worth up to $515 million, to partner on a fragment-based drug ...

Astex Pharmaceuticals on Cambridge Science Park has tapped into a gold mine through a mega-deal with Genentech, a member of ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...

CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a ...

Astex Pharmaceuticals has initiated phase 2, open-label, single-arm, clinical trials evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment ...

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic ...

Astex signs research collaboration and license agreement with Genentech for breast cancer therapy: Cambridge, UK Tuesday, July 7, 2026, 16:00 Hrs [IST] Astex Pharmaceuticals, a wh ...

Astex to receive an upfront and potential milestone payments, totalling more than $490 million as well as tiered royalties on net sales CAMBRIDGE, United Kingdom, July 06, 2026 (GLOBE NEWSWIRE) -- ...